STOCK TITAN

Oncocyte Corporation - OCX STOCK NEWS

Welcome to our dedicated page for Oncocyte Corporation news (Ticker: OCX), a resource for investors and traders seeking the latest updates and insights on Oncocyte Corporation stock.

Oncocyte Corporation (OCX) is a pioneering precision diagnostics company dedicated to the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics aimed at facilitating clinical decision-making in the early detection of cancer. The company focuses on molecular tests that address high unmet needs in the diagnosis of lung, breast, and bladder cancers, conditions where current diagnostic standards are often ambiguous, costly, and invasive. Oncocyte's tests are developed based on a proprietary set of biomarkers, designed to differentiate between benign and malignant nodules or masses.

Oncocyte’s flagship products include:

  • DetermaIO™: A gene expression test that assesses the tumor microenvironment to predict response to immunotherapies.
  • DetermaCNI™: A blood-based monitoring tool for therapeutic efficacy in cancer patients.
  • VitaGraft™: A blood-based solid organ transplantation monitoring test.
  • GraftAssure™: A research-use-only monitoring test for solid organ transplantation.

The company has made significant strides in expanding its diagnostic capabilities and achieving key regulatory and commercial milestones. In 2023, Oncocyte secured reimbursement for VitaGraft™ Kidney, manufactured the initial lots of GraftAssure RUO, and entered a strategic partnership with Bio-Rad Laboratories to commercialize GraftAssure and develop VitaGraft Kidney IVD. This partnership, along with a successful $15.8 million private placement offering, positions Oncocyte well to meet its critical commercial and regulatory goals.

Oncocyte continues to be supported by strong core investors and aims to provide clarity and confidence to physicians and their patients through its groundbreaking diagnostic tests. For more information, visit www.oncocyte.com.

Rhea-AI Summary

Oncocyte Corporation (Nasdaq: OCX) has initiated an underwritten public offering of common stock and warrants, with plans to grant underwriters a 30-day option for an additional 15% of shares. The offering's completion is subject to market conditions. Proceeds will primarily support the commercialization of DetermaRx™, the development of DetermaIO™ and TheraSure™, and other tests in its pipeline, alongside costs from a collaboration with Life Technologies Corporation. A shelf registration statement was previously declared effective in June 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
-
Rhea-AI Summary

Oncocyte Corporation (Nasdaq: OCX) announced a registered direct offering of 11,765 shares of Series A Convertible Preferred Stock, convertible into 7,689,542 shares of common stock at $1.53 per share. The offering aims to raise approximately $10 million in gross proceeds to enhance commercialization of DetermaRx™, DetermaIO™, and TheraSure™, among others. The Preferred Stock carries a 6% annual dividend and requires redemption by April 8, 2024 if not converted. There is no public trading market for the Preferred Stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
-
Rhea-AI Summary

Oncocyte Corporation (Nasdaq: OCX) announced findings from a real-world cohort study demonstrating that its DetermaIO test can effectively predict responses to immunotherapy in patients with bladder cancer. The study validated the test's capacity to identify responders to immune checkpoint inhibitors (ICIs) and confirmed previous results from the IMvigor210 trial. DetermaIO, launched in Q4 2021, assesses the tumor microenvironment, providing critical insights that could improve patient treatment decisions and outcomes. The findings were presented at the AACR Annual Meeting 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.51%
Tags
none
Rhea-AI Summary

Oncocyte Corporation (Nasdaq: OCX) announced it will present new data on its DetermaIO™ test at the AACR Annual Meeting 2022 from April 8-13 in New Orleans. The 27-gene expression test helps identify patients with bladder cancer who are likely to respond to immune checkpoint inhibitors (ICIs). This new analysis confirms previous findings linking the IO Score to responses to Genentech’s Tecentriq® therapy. DetermaIO is the first test to evaluate the entire tumor microenvironment, enhancing therapeutic decision-making for patients undergoing immunotherapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
conferences
-
Rhea-AI Summary

Oncocyte Corporation (Nasdaq: OCX) reported significant growth in its Q4 2021 results, with revenues up 104% year-over-year to $3.6 million and test volume increasing 54%. The company announced a strategic partnership with Thermo Fisher Scientific for distributed in vitro diagnostic assays. Notably, their DetermaCNI blood monitoring test has shown promising results for detecting cancer recurrence, and they are on track to launch the TheraSure Transplant Monitor in March 2022. Despite growing revenues, operating losses widened to $35.7 million in Q4 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.86%
Tags
-
Rhea-AI Summary

Oncocyte Corporation (Nasdaq: OCX) has announced the release of its financial and operating results for the fourth quarter and year ending December 31, 2021, set for March 10, 2022, post U.S. market close. A conference call will follow at 4:30 PM ET to discuss the results and corporate developments. Oncocyte specializes in precision diagnostics for cancer treatment, offering tests like DetermaRx™ and DetermaIO™ that aid in the diagnosis and monitoring of cancer. The company aims to enhance patient outcomes through its innovative diagnostics solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
conferences earnings
Rhea-AI Summary

Oncocyte Corporation (Nasdaq: OCX) announced participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Management will present during a fireside chat on February 15, 2022, at 4:30 PM EST. The conference aims to enhance patient outcomes through personalized diagnostic insights. Notably, Oncocyte offers proprietary tests like DetermaRx™ and DetermaIO™ to assist in cancer diagnosis and treatment. Investors can reach out to BTIG representatives for meeting opportunities, though the presentation won't be webcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
conferences
-
Rhea-AI Summary

Oncocyte Corporation (Nasdaq: OCX) announced a collaboration with Thermo Fisher Scientific to develop and co-market in vitro diagnostic (IVD) assays utilizing Thermo Fisher’s Ion Torrent Genexus System. The agreement includes clinical validation of the Oncomine Comprehensive Assay Plus for tumor profiling and development of Oncocyte’s DetermaIO™ test. The IVD assays aim to enhance precision medicine accessibility, potentially benefiting a significant portion of newly diagnosed cancer patients. The partnership leverages Thermo Fisher’s global capabilities to expand IVD availability beyond the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.2%
Tags
none
-
Rhea-AI Summary

Oncocyte Corporation (Nasdaq: OCX) announced that its DetermaCNI test has demonstrated higher sensitivity in detecting cancer recurrence compared to standard biomarkers, showcasing 91% sensitivity at diagnosis and 86% sensitivity during treatment, with a low false positive rate of 5%. This blood-based test offers a genome-wide assessment without the need for tissue samples, making it an innovative solution for cancer monitoring, particularly for ovarian cancer patients, addressing significant unmet needs in treatment evaluation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
none
Rhea-AI Summary

Oncocyte Corporation (OCX) announced significant advancements for its DetermaIO test at the SABCS 2021, showcasing its ability to predict responses to immunotherapies in triple negative breast cancer (TNBC). The test achieved a 92% concordance with RNA-sequencing data, emphasizing its reliability across different platforms. It is expected to enhance patient outcomes by identifying candidates for immunotherapy, thus addressing a critical unmet need. DetermaIO has previously demonstrated efficacy in other cancers, reinforcing its potential for pan-cancer diagnostic testing globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.28%
Tags
none

FAQ

What is the current stock price of Oncocyte Corporation (OCX)?

The current stock price of Oncocyte Corporation (OCX) is $2.19 as of December 20, 2024.

What is the market cap of Oncocyte Corporation (OCX)?

The market cap of Oncocyte Corporation (OCX) is approximately 37.5M.

What does Oncocyte Corporation specialize in?

Oncocyte Corporation focuses on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics for the early detection of cancer.

What types of cancer does Oncocyte's diagnostics target?

Oncocyte's diagnostics target lung, breast, and bladder cancers.

What are some of Oncocyte's key products?

Key products include DetermaIO™, DetermaCNI™, VitaGraft™, and GraftAssure™.

How does Oncocyte's DetermaIO™ test work?

DetermaIO™ is a gene expression test that evaluates the tumor microenvironment to predict response to immunotherapies.

What recent achievements has Oncocyte made?

In 2023, Oncocyte achieved reimbursement for VitaGraft™ Kidney, manufactured the first lots of GraftAssure RUO, and entered a partnership with Bio-Rad Laboratories.

Who are some of Oncocyte's partners?

Oncocyte has a key partnership with Bio-Rad Laboratories for the commercialization of GraftAssure and the development of VitaGraft Kidney IVD.

What is the purpose of Oncocyte's VitaGraft™ test?

VitaGraft™ is a blood-based test used for monitoring solid organ transplantation.

What is GraftAssure™ used for?

GraftAssure™ is a research-use-only blood-based test for monitoring solid organ transplantation.

How does Oncocyte support its operations financially?

Oncocyte is supported by strong core investors and has raised funds through private placement offerings, including a recent $15.8 million offering.

Where can I find more information about Oncocyte Corporation?

More information can be found on their official website at www.oncocyte.com.

Oncocyte Corporation

Nasdaq:OCX

OCX Rankings

OCX Stock Data

37.54M
13.61M
15.96%
50.6%
1.34%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States of America
IRVINE